Adia Nutrition, Inc. (ADIA)
Oxford Ledge is still expanding full research coverage of ADIA. A delayed quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
ADIA Nutrition operates medical clinics and sells FDA-registered stem cell therapies and supplements for regenerative medicine and health applications.
Source: 10-K (2025-12-31) · AI-generated analysis. Not investment advice. May contain errors.
SEC filings
- 10-Q Quarterly financial report (unaudited) 2026-05-15
- 10-K Annual financial report with audited statements 2026-03-31
- 8-K Departure/election of directors or officers; Financial statements and exhibits 2014-01-29
- 8-K Other material event; Financial statements and exhibits 2013-12-27
- 8-K Other material event; Financial statements and exhibits 2013-12-09
Source: SEC EDGAR.
Annual results
2 years of annual figures for ADIA, as filed with the SEC. Figures are as reported and are not restated or adjusted.
| Fiscal year | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| 2025 | $700,508 | -$395,464 | $0.00 |
| 2024 | $6,380 | -$181,067 | $0.00 |
Source: SEC EDGAR (XBRL company facts). Full statements and ratios in the terminal.
- Open ADIA in the Oxford Ledge terminal — delayed quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.